Given the restrictive Medicare coverage, Biogen expects limited Aduhelm prescription and usage in routine clinical practice for enrollment in the real-world study. (Biogen) For Biogen’s ill-fated ...

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move the drug into ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...